United States: Food, Drugs, Healthcare, Life Sciences

This digest covers key virtual and digital health regulatory and public policy developments during March and early April 2026 from the United States, United Kingdom, and European Union.

The DEA's April 2026 final order creates a federal registration pathway for state-licensed medical marijuana operators, placing FDA-approved and state-licensed medical cannabis products on Schedule III...

On April 15, 2026, the European Data Protection Board ("EDPB") adopted Guidelines 1/2026 on the processing of personal data for scientific research purposes (the "Guidelines").

One does not need to be Miranda Priestly to observe that discounts are a trending topic for the US Department of Health and Human Services Office of Inspector General (OIG) advisory opinions (AOs).

This digest covers key virtual and digital health regulatory and public policy developments during March and early April 2026 from the United States, United Kingdom, and European Union.

AbbVie advances its SKYRIZI subcutaneous treatment for Crohn's disease with FDA submission, while investing $1.4 billion in a North Carolina manufacturing campus.

One does not need to be Miranda Priestly to observe that discounts are a trending topic for the US Department of Health and Human Services Office of Inspector General (OIG) advisory opinions (AOs).

This digest covers key virtual and digital health regulatory and public policy developments during March and early April 2026 from the United States, United Kingdom, and European Union.

This comprehensive update covers significant regulatory developments affecting retirement and health plans, including the DOL's proposed safe harbor for investment selection, the reinstatement of the Five-Part Fiduciary Test, and critical court decisions on ERISA compliance. The bulletin also addresses emerging issues in prescription drug pricing litigation and provides essential compliance deadlines for plan administrators.